DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Export Market in India 2021" report has been added to ResearchAndMarkets.com's offering.
The pharmaceutical industry has witnessed rapid growth in the past few decades and is expected to develop further, owing to huge export possibilities.
Companies profiled
- Sun Pharmaceuticals Industries Limited
- Aurobindo Pharma Limited
- Lupin Limited
- Dr. Reddy's Laboratories Limited
- Cipla Limited
- Cadila Healthcare Limited
- Glenmark Pharmaceuticals Limited
- Torrent Pharmaceuticals Limited
- Alkem Laboratories Limited
- Divi's Laboratories Limited
The business caters to 50% of the global demand of various vaccines, 40% of generic medicines demand in the US, and 25% of all medication in the UK. Pharmaceutical exports rose by 24.48% between FY 2020 and FY 2021 to reach INR 1,437.38 Bn in FY 2021. This was despite the global industry reduced by almost 2% in 2020 on account of COVID-19. As of 2021, nearly all medicines made domestically were low-cost generic drugs that comprise most of pharmaceutical export of the country.
Impact of COVID-19:
The onslaught of COVID-19 and the nationwide lockdown severely impacted the healthcare and pharmaceutical infrastructure, and the country's economy. Travel restrictions, shortage of workforce, disruption in world trade, and bottleneck in logistics impacted the supply chain of pharmaceutical products.
During the second wave, key market players took major steps as per regulatory guidelines with smart solutions to tackle the supply-demand gap. As of 2021, India shipped over INR 1,349 Bn worth drugs to over 200 nations, ranging from the highly regulated markets in North America and Europe to countries with small pharmaceutical markets.
Key Topics Covered:
Chapter 1: Executive summary
Chapter 2: Socio-economic indicators
Chapter 3: Introduction
3.1. Market definition and structure
Chapter 4: Market overview
4.1. Pharmaceutical export market in India - An overview
4.2. Export of pharmaceutical products (FY 2018 - FY 2021)
4.3. Country-wise export of pharmaceutical products (FY 2020 - FY 2021)
Chapter 5: COVID-19 impact assessment
5.1. Overview
5.1.1. Positive impact
5.1.2. Negative impact
5.2. Post-pandemic scenario
Chapter 6: Trade analysis
6.1. Export of pharmaceutical products
6.1.1. Commodity-wise export - Based on value
6.1.2. Country-wise export - Based on value
6.1.3. Other exports - Based on value
Chapter 7: Market influencers
7.1. Market drivers
7.2. Market challenges
Chapter 8: Government initiatives
8.1 Government initiatives
Chapter 9: Competitive landscape
9.1. Sun Pharmaceuticals Industries Limited
9.2. Aurobindo Pharma Limited
9.3. Lupin Limited
9.4. Dr. Reddy's Laboratories Limited
9.5. Cipla Limited
9.6. Cadila Healthcare Limited
9.7. Glenmark Pharmaceuticals Limited
9.8. Torrent Pharmaceuticals Limited
9.9. Alkem Laboratories Limited
9.10. Divi's Laboratories Limited
Chapter 9: Recent developments
Chapter 10: Appendix
For more information about this report visit https://www.researchandmarkets.com/r/clcd8z
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
